Table 3. Efficacy and Safety End Points (n = 86).

Variables	Group I (TNK; n = 45)	Group II (placebo; n = 41)	P-value
Primary composite outcome within 7 days	2 (4.5%)	8 (20%)	0.04
Secondary end points
All cause death	2 (4.5%)	2 (5%)	0.3
Hemodynamic decompensation	2 (4.5%)	8 (20%)	0.04
Recurrent PE within 7 days	2 (4.5%)	1 (2%)	0.3
Rehospitalization within 30 days	2 (4.5%)	4 (10%)	0.29
Death within 30 days	2 (4.5%)	2 (5%)	0.18
Others
Mean PASP at D7 (mm Hg)	32.80 ± 4.02	38.13 ± 4.49	0.04
Mean ↓ in PASP from baseline (mm Hg)	14.10 ± 3.95	11.08 ± 4.23	0.003
Improvement in RV function	31 (70%)	16 (40%)	0.001
Need for mechanical ventilation	2 (4.5%)	2 (5%)	0.6
Mean hospital stay (days)	8.1 ± 2.51	11.1 ± 2.14	0.001
Safety end points (bleeding within D7)
Major bleeding	1 (2%)	1 (2%)	0.45
Minor Bleeding	7 (16%)	5 (12%)	0.04
Hemorrhagic stroke	1 (2%)	0 (0%)	0

PE: pulmonary embolism; PASP: pulmonary artery systolic pressure; RV: right ventricle.